drugset / Trial / NCT06703203
Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this experiment is to evaluate the safety and immunogenicity of the 26 valent pneumococcal conjugate vaccine in the population aged 2 months and above.
Timeline
- Start
- 2025-07-17
- Primary completion
- 2025-08-05
- Completion
- 2026-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 26-Valent pneumococcal conjugate vaccine | Vaccine | 0.5 ml | — |
| Subject | Pneumovax 23 | Vaccine | 0.5 ml | — |
| Subject | Prevnar 13 | Vaccine | 0.5 ml | — |
Indications
No indication recorded.